OTCMKTS:BRTXQ BioRestorative Therapies (BRTXQ) Stock Price, News & Analysis $1.85 +0.07 (+3.93%) As of 04/2/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsBuy This Stock About BioRestorative Therapies Stock (OTCMKTS:BRTXQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BRTXQ alerts:Sign Up Key Stats Today's Range$1.75▼$1.8850-Day Range$1.43▼$2.4952-Week Range$0.00▼$0.06Volume50,428 shsAverage Volume62.17 million shsMarket Capitalization$3.03 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Read More… Remove Ads Receive BRTXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address BRTXQ Stock News HeadlinesBioRestorative Therapies (OTCMKTS:BRTXQ) Trading Up 3.9% - What's Next?April 4 at 1:55 AM | americanbankingnews.comBioRestorative Therapies Reports 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 5, 2025 | Porter & Company (Ad)BioRestorative Therapies to provide clinical pipeline update on February 27February 25, 2025 | markets.businessinsider.comBioRestorative Therapies Showcases Promising Stem Cell AdvancesNovember 14, 2024 | markets.businessinsider.comBioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical DataNovember 13, 2024 | markets.businessinsider.comBioRestorative Therapies reports Phase 2 BRTX-100 clinical dataNovember 13, 2024 | markets.businessinsider.comBioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased FunctionNovember 13, 2024 | benzinga.comSee More Headlines BRTXQ Stock Analysis - Frequently Asked Questions How have BRTXQ shares performed this year? BioRestorative Therapies' stock was trading at $1.43 on January 1st, 2025. Since then, BRTXQ stock has increased by 29.4% and is now trading at $1.85. View the best growth stocks for 2025 here. How do I buy shares of BioRestorative Therapies? Shares of BRTXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryHealthcare Current SymbolOTCMKTS:BRTXQ CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales27,575.53 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-2.72Miscellaneous Outstanding Shares1,639,626,000Free FloatN/AMarket Cap$3.03 billion OptionableNot Optionable Beta102.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:BRTXQ) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.